Five Prime Therapeutics Inc

Five Prime Therapeutics — Investor Day (December 2016)

77 slides from Five Prime Therapeutics's investor day presentation, Dec 8, 2016

  1. Slide 1: R&D Day

    R&D Day NASDAQ:FPRX December 8, 2016 Exhibit 99.1

  2. Slide 2: Forward-Looking Statements Disclaimer

    This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate" and similar expressions (as well as other words or expressions referencing future events or circumstances) are

  3. Slide 3: R&D Overview

    R&D Overview Rusty Williams, M.D., Ph.D. Founder, President & Chief Executive Officer

  4. Slide 4: Reprogramming the Tumor Microenvironment

    …systematically testing the extracellular proteins that control it REPROGRAMMING THE TUMOR MICROENVIRONMENT © 2016 Five Prime Therapeutics, Inc. All Rights Reserved

  5. Slide 5: Five Prime's Unique Platform: Use Nearly Every Extracellular Protein

    Five Prime’s Unique Platform: Use Nearly Every Extracellular Protein to Identify Best New Protein Drugs and Antibody Targets Library of > 5700 Extracellular Proteins Soluble Extracellular Domains Cell Surface Receptors/Ligands Secreted Factors © 2016 Five Prime Therapeutics, Inc. All Rights Reserved

  6. Slide 6: Using our Platform to Find New Drugs to Reprogram Key Immune Cells

    Using our Platform to Find New Drugs to Reprogram Key Immune Cells in the Tumor Microenvironment © 2016 Five Prime Therapeutics, Inc. All Rights Reserved Discovering novel protein drugs Targeting key immune cells Extracellular Proteins Tumor Cell Immune Cell Immune Cell Unique Comprehensive Systemat

  7. Slide 7: Multiple Approaches to Understand Best Antibody Targets

    © 2016 Five Prime Therapeutics, Inc. All Rights Reserved Multiple Approaches to Understand Which Proteins in Our Library are the Best Antibody Targets or Drugs Themselves CD8 T cell screen TReg cell screen Immunome x Immunome In vivo screens Single agent Combinations with PD1 blockers Unique I-O Tar

  8. Slide 8: Oncology-Focused Pipeline with Multiple Clinical Candidates

    Oncology-Focused Pipeline with Multiple Clinical Candidates © 2016 Five Prime Therapeutics, Inc. All Rights Reserved Program Indications Lead selection IND-enabling activities Phase 1 Phase 1b Phase 2 Cabiralizumab (FPA008) CSF-1R antibody FPA144 FGFR2b antibody FP-1039 FGF ligand trap Multiple tumo

  9. Slide 9: Progress in Building Out a Broad and Unique I-O Pipeline

    Progress in Building Out a Broad and Unique I-O Pipeline © 2016 Five Prime Therapeutics, Inc. All Rights Reserved CD8 T cell screen TReg cell screen Immunome x Immunome In vivo screens Single agent Combinations with PD1 blockers Discovery Programs cabiralizumab (anti-CSF-1R) FPA144 (anti-FGRF2b) FP-

  10. Slide 10: Research and Preclinical Pipeline

    Research and Preclinical Pipeline Art Brace, Ph.D. Executive Director, Immuno-Oncology Discovery

  11. Slide 11: Progress in Building Out a Broad and Unique I-O Pipeline

    Progress in Building Out a Broad and Unique I-O Pipeline © 2016 Five Prime Therapeutics, Inc. All Rights Reserved cabiralizumab (anti-CSF-1R) FPA144 (anti-FGRF2b) FP-1039 (FGF ligand trap) Clinical Trials Data read-outs in 2017 Preclinical Programs Three in IND-enabling studies First IND in 2017 FPA

  12. Slide 12: Screening a Library of the Extracellular Proteome

    Five Prime’s Unique Platform: Screening a Library of the Extracellular Proteome to Identify Novel Targets and Therapeutics Receptor-Ligand Matching Library of > 5700 Extracellular Proteins Proprietary Screens Cell-based Screens In Vivo Screens Soluble Extracellular Domains Cell Surface Receptors/Lig

  13. Slide 13: Monocyte Activation Screening Led to Cabiralizumab

    Five Prime Monocyte Activation Screening Led to the Development of Cabiralizumab (FPA008) © 2016 Five Prime Therapeutics, Inc. All Rights Reserved Discovered IL-34 in monocyte activation screening Discovered that the IL-34 receptor is CSF1R Determined the pathway selectively stimulates M2 macrophage

  14. Slide 14: Multiple Approaches to Target Immune Cell Subsets

    Actively Pursuing Multiple Approaches to Target Different Immune Cell Subsets in the Tumor Microenvironment © 2016 Five Prime Therapeutics, Inc. All Rights Reserved CD8 T cell TAM Dendritic cell Treg NK cell Extracellular Proteins Tumor Cell Immune Cell Immune Cell Cell-based screening Effector T ce

  15. Slide 15: Unique Immunome x Immunome Protein Interaction Screen

    Unique Immunome x Immunome Protein Interaction Screen Identifying the Proteome Interaction Network © 2016 Five Prime Therapeutics, Inc. All Rights Reserved Extracellular Proteins Tumor Cell Immune Cell Immune Cell Focused on 700 proteins likely to modulate the immune system (immunome) Tested each pr

  16. Slide 16: Screen of ~500k Interactions Identified Over 100 Novel Interactions

    Our Screen of ~500k Immune Protein Interactions Identified More Than 100 Previously Unknown Interactions Identified well-known interactions spanning a wide range of reported affinities Discovered over a hundred novel interactions Normalized Binding Response Protein Pair (~500K) ICOSLG:ICOS CD80:CTLA

  17. Slide 17: Prioritizing Immunome x Immunome Hits for Validation

    Prioritizing Immunome x Immunome Hits for Validation High priority I-O targets for validation Hit prioritization Immune cell expression profile Tumor and normal expression Connection to immune regulation and/ or tumor biology Activity in FivePrime functional screens >100 novel interactions © 2016 Fi

  18. Slide 18: In Vitro Co-culture Screen to Identify T Cell Modulators

    In Vitro Co-culture Screen to Identify T Cell Modulators © 2016 Five Prime Therapeutics, Inc. All Rights Reserved CD8 T cell TAM Dendritic cell Treg NK cell Extracellular Proteins Tumor Cell Immune Cell Immune Cell Functional screen using an IFNg readout Antigen-presenting cells co-cultured with pri

  19. Slide 19: Screening Detects T Cell Stimulators and Inhibitors

    Relative T Cell Activity Individual Library Proteins CD80 PD-L1 4-1BBL CD86 ICOSLG CTLA4 GITRL Screening >2000 Proteins Detects T cell Stimulators and Inhibitors © 2016 Five Prime Therapeutics, Inc. All Rights Reserved Robust assay response to known T cell agonists and inhibitors Identified addition

  20. Slide 20: Immunome Data Helps Prioritize Functional Screen Hits

    Relative T Cell Activity Individual Library Proteins CD80 PD-L1 4-1BBL CD86 ICOSLG CTLA4 GITRL Data from Immunome x Immunome Screen Helps Prioritize Functional Screen Hits Binding data from Immunome x Immunome screen identifies proteins potentially working in a functional pathway Activators Inhibito

  21. Slide 21: Unique Approach to Screen for Immuno-Modulatory Targets In Vivo

    Our Unique Approach to Screen for Immuno-Modulatory Targets In Vivo © 2016 Five Prime Therapeutics, Inc. All Rights Reserved Bypasses protein scale up, purification, and formulation Achieves high blood levels for weeks after administration Inject naked DNA vector encoding protein of interest DNA ins

  22. Slide 22: In Vivo Screen Identifies Immune Activators and Inhibitors

    0 100 200 300 400 Individual Library Proteins Screened Potential agonist hits Potential checkpoint hits Testing models with different tumor immune microenvironments Testing proteins in combination with known checkpoint inhibitors, including anti-PD1 In Vivo Screen of the Immunome Identifies Both Imm

  23. Slide 23: Multiple Approaches to Understand Best Antibody Targets

    © 2016 Five Prime Therapeutics, Inc. All Rights Reserved Multiple Approaches to Understand Which Proteins in Our Library are the Best Antibody Targets or Drugs Themselves CD8 T cell screen TReg cell screen Immunome x Immunome In vivo screens Single agent Combinations with PD1 blockers Unique I-O Tar

  24. Slide 24: FivePrime I-O Research Pipeline

    FivePrime I-O Research Pipeline Luis Borges, Ph.D. Senior Vice President of Research

  25. Slide 25: Progress in Building Out a Broad and Unique I-O Pipeline

    cabiralizumab (anti-CSF-1R) FPA144 (anti-FGRF2b) FP-1039 (FGF ligand trap) Clinical Trials Data read-outs in 2017 CD8 T cell screen TReg cell screen Immunome x Immunome In vivo screens Single agent Combinations with PD1 blockers Discovery Programs Progress in Building Out a Broad and Unique I-O Pipe

  26. Slide 26: Oncology-Focused Pipeline with Multiple Clinical Candidates

    Oncology-Focused Pipeline with Multiple Clinical Candidates © 2016 Five Prime Therapeutics, Inc. All Rights Reserved Program Indications Lead selection IND-enabling activities Phase 1 Phase 1b Phase 2 Cabiralizumab (FPA008) CSF-1R antibody FPA144 FGFR2b antibody FP-1039 FGF ligand trap FPT155 CD80-F

  27. Slide 27: FPT155: A Soluble CD80-Fc

    FPT155 A Soluble CD80-Fc That Modulates Multiple Signaling Pathways On T Cells

  28. Slide 28: CD80-Fc Identified as Potent Agonist in In Vivo Screen

    © 2016 Five Prime Therapeutics, Inc. All Rights Reserved CD80-Fc Was Originally Identified as One of the Most Potent Agonists in Our In Vivo Screen CD80-Fc was one of most potent agonists in the in vivo screen of over 500 proteins 0 100 200 300 400 Individual Proteins Screened Potential agonist hits

  29. Slide 29: CD80 Modulates T Cell Priming and Activation

    © 2016 Five Prime Therapeutics, Inc. All Rights Reserved CD80 Is a B7-Family Member That Is Involved in Modulating T Cell Priming and Activation Antigen presenting cell T cell (+) signal CD80 CTLA4 CD28 (-) signal CD80 CD80 is a co-stimulatory molecule expressed on antigen presenting cells CD80 bind

  30. Slide 30: FPT155 Regulates Multiple Signaling Pathways On T Cells

    FPT155 Regulates Multiple Signaling Pathways On T Cells © 2016 Five Prime Therapeutics, Inc. All Rights Reserved CD80-Fc is an agonist of CD28 CD80-Fc can block CTLA4 to facilitate T cell activation CD80-Fc can block PD-L1 to facilitate T cell activation in the tumor T cell T cell Myeloid cell or Tu

  31. Slide 31: FPT155 Provides Co-Stimulatory Signal Without Superagonist Activity

    © 2016 Five Prime Therapeutics, Inc. All Rights Reserved FPT155 Provides a Co-Stimulatory Signal for T Cell Activation, But Does Not Have “Superagonist Activity”

  32. Slide 32: mFPT155 Has Potent Anti-tumor Activity in Murine Models

    © 2016 Five Prime Therapeutics, Inc. All Rights Reserved The Murine Surrogate mFPT155 Has Potent Anti-tumor Activity in Various Murine Tumor Models mFPT155 promotes T cell recruitment into tumors

  33. Slide 33: mFPT155 Induces Long Term Anti-Tumor Immunity

    © 2016 Five Prime Therapeutics, Inc. All Rights Reserved mFPT155 Treatment Induces Long Term Anti-Tumor Immunity Mice re-challenged with tumors 8 weeks after clearance of initial primary tumor were protected from tumor growth

  34. Slide 34: FPT155 Is On Track for IND Filing in Mid 2018

    FPT155 lead has been selected Non-human primate studies are underway Manufacturing activities have been initiated IND filing planned in mid 2018 © 2016 Five Prime Therapeutics, Inc. All Rights Reserved FPT155 Is On Track for IND Filing in Mid 2018

  35. Slide 35: FPA154: Multivalent Antibody Targeting GITR

    FPA154 A Novel, Multivalent Therapeutic Candidate Antibody Targeting GITR

  36. Slide 36: GITRL Identified as Potent Agonist in In Vivo Screen

    GITRL Was Originally Identified as Another Potent Agonist in Our In Vivo Screen 0 100 200 300 400 Individual Proteins Screened Potential agonist hits Potential checkpoint hits GITRL Tumor Growth Volume % CTLA4 GITR, the receptor for GITRL, is a member of the TNF receptor superfamily GITR is preferen

  37. Slide 37: FPA154 Has Increased Valency Over Conventional Antibodies

    FPA154 Has Increased Valency Over Conventional Antibodies © 2016 Five Prime Therapeutics, Inc. All Rights Reserved Conventional Antibody Two antigen binding sites FPA154 Four antigen binding sites Fc region Fc region Variable domains Variable domains

  38. Slide 38: FPA154 Is a More Potent GITR Agonist

    © 2016 Five Prime Therapeutics, Inc. All Rights Reserved FPA154 Is a More Potent GITR Agonist Than Conventional GITR Antibodies Tetravalent FPA154 promotes more efficient GITR crosslinking and signaling than conventional bivalent antibodies HEK293/NFκB - human GITR reporter cell line FPA154 Bivalent

  39. Slide 39: FPA154 Improved CD8 T Cell Agonism and Treg Depletion

    © 2016 Five Prime Therapeutics, Inc. All Rights Reserved FPA154 Is Designed to Have Improved CD8 T Cell Agonistic Activity in Conjunction with Potent Treg Depletion Activity Effector T cell FPA154 GITR Depletion of Regulatory T cells through ADCC Treg NK cell FPA154 GITR FPA154 has predominantly ago

  40. Slide 40: cmFPA154 Suppresses Tumor Growth in Multiple Models

    © 2016 Five Prime Therapeutics, Inc. All Rights Reserved The Murine Surrogate cmFPA154 Antibody Suppresses Tumor Growth in Multiple Tumor Models CT26 Tumor Model MC38 Tumor Model cmFPA154 is tetravalent anti-GITR antibody derived from the same single domain antibody that was used to generate FPA154

  41. Slide 41: Mice Eliminating Tumors Resist Re-Challenge

    © 2016 Five Prime Therapeutics, Inc. All Rights Reserved Mice That Eliminated Tumors in Response to cmFPA154 Are Resistant to Tumor Re-Challenge Naive mice (n=5) Re-challenged mice (n=10) CT26 Tumor Model Days post-inoculation

  42. Slide 42: cmFPA154 and Anti-PD1 Have Synergistic Activity

    © 2016 Five Prime Therapeutics, Inc. All Rights Reserved The Combination of cmFPA154 and an Anti-PD1 Antibody Has Synergistic Anti-Tumor Activity mIgG2a cmFPA154 Anti-PD1 Ab MC38 Tumor Model cmFPA154 + Anti-PD1 Ab

  43. Slide 43: FPA154 Is On Track for IND Filing in Late 2017

    FPA154 lead has been selected Non-human primate studies are underway Manufacturing activities have been initiated IND filing planned in fourth quarter 2017 © 2016 Five Prime Therapeutics, Inc. All Rights Reserved FPA154 Is On Track for IND Filing in Late 2017

  44. Slide 44: FPA150: Antibody Targeting B7-H4 Checkpoint Pathway

    FPA150 A Therapeutic Candidate Antibody Targeting the B7-H4 Checkpoint Pathway

  45. Slide 45: B7-H4 Is a Member of the B7 Family of Checkpoint Inhibitors

    B7-H4 Is a Member of the B7 Family of Checkpoint Inhibitors © 2016 Five Prime Therapeutics, Inc. All Rights Reserved B7-H4 shares significant homology with other B7 family members, including PD-L1 and PD-L2 B7-H4 is expressed in several human tumors and its expression tends to correlate with poor pr

  46. Slide 46: B7-H4 Is a T Cell Checkpoint Inhibitor

    B7-H4 Is a T Cell Checkpoint Inhibitor © 2016 Five Prime Therapeutics, Inc. All Rights Reserved Dangaj et al., Can Res, 2013 Anti-CD3 stimulation + Control protein or B7-H4 Cell Proliferation IFN-g Secretion B7-H4 inhibits Human T Cell proliferation and IFNg secretion

  47. Slide 47: B7-H4 Is Over-Expressed in Breast Cancer

    B7-H4 Is Over-Expressed in Breast Cancer © 2016 Five Prime Therapeutics, Inc. All Rights Reserved Salceda S et al., Exp Cell Res, 2005; Mugler KC et al., Appl IHC Mol Morphol, 2007 Invasive Ductal Carcinoma Normal Breast Epithelium Ductal Adenocarcinoma Normal Adjacent Breast Tissue

  48. Slide 48: B7-H4 Over-Expressed in Gynecological Cancers

    B7-H4 Is Over-Expressed in Gynecological Cancers, Including Ovarian and Endometrial Cancer © 2016 Five Prime Therapeutics, Inc. All Rights Reserved Salceda S et al., Exp Cell Res, 2005; Miyatake M et al., Gynecol Oncol, 2007 Endometrial Carcinoma Normal Proliferative Endometrium Serous Adenocarcinom

  49. Slide 49: B7-H4 Over-Expressed in Lung and Pancreatic Cancer

    B7-H4 Is Over-Expressed in Additional Solid Tumor Indications, Including Lung and Pancreatic Cancer © 2016 Five Prime Therapeutics, Inc. All Rights Reserved Pancreatic Cancer Normal Pancreas Lung Squamous Cell Carcinoma Normal Lung Choi IH et al., JI, 2003; Xu H et al., Oncol Lett, 2016

  50. Slide 50: FPA150 Engineered with Two Distinct Mechanisms of Action

    FPA150 is Engineered to Possess Two Distinct Mechanisms of Action © 2016 Five Prime Therapeutics, Inc. All Rights Reserved FPA150 blocks B7-H4 from sending an inhibitory signal to T cells FPA150 is engineered for enhanced ADCC B7-H4 MHC T cell TCR Tumor Cell FPA150 + T Cell checkpoint blockade B7-H4

  51. Slide 51: FPA150 Is On Track for IND Filing in Late 2017

    FPA150 lead selected Non-human primate studies are underway Manufacturing activities have been initiated Developing patient selection test IND filing planned in fourth quarter 2017 FPA150 Is On Track for IND Filing in Late 2017 © 2016 Five Prime Therapeutics, Inc. All Rights Reserved

  52. Slide 52: Our I-O Research Pipeline Is Diversified and Robust

    Our I-O Research Pipeline Is Diversified and Robust We Plan to File One New IND per Year Starting 2017 © 2016 Five Prime Therapeutics, Inc. All Rights Reserved On target to file an IND in late 2017 and 1 more yearly thereafter In addition, we are exploring novel I-O targets that modulate both the ad

  53. Slide 53: Cabiralizumab (FPA008) - Antibody for Macrophage-Dependent Diseases

    Cabiralizumab (FPA008) - Antibody for Macrophage-Dependent Diseases Robert Sikorski, M.D., Ph.D. Senior Vice President and Chief Medical Officer

  54. Slide 54: Progress in Building Out a Broad and Unique I-O Pipeline

    Progress in Building Out a Broad and Unique I-O Pipeline CD8 T cell screen TReg cell screen Immunome x Immunome In vivo screens Single agent Combinations with PD1 blockers Discovery Programs © 2016 Five Prime Therapeutics, Inc. All Rights Reserved Preclinical Programs Three in IND-enabling studies F

  55. Slide 55: Our I-O Research Pipeline Is Diversified and Robust

    Our I-O Research Pipeline Is Diversified and Robust © 2016 Five Prime Therapeutics, Inc. All Rights Reserved CD8 T cell TAM Dendritic cell Treg NK cell Extracellular Proteins Tumor Cell Immune Cell Immune Cell

  56. Slide 56: Cabiralizumab: A Product of the Five Prime Platform

    © 2016 Five Prime Therapeutics, Inc. All Rights Reserved Cabiralizumab (FPA008): A Product of the Five Prime Platform CSF-1 IL-34 Cabiralizumab (FPA008) antibody inhibits CSF-1R and blocks activation and survival of macrophages and monocytes Five Prime discovered IL-34, one of the two ligands for CS

  57. Slide 57: Cabiralizumab Targets Immuno-Suppressive Tumor-Associated Macrophages

    Control © 2016 Five Prime Therapeutics, Inc. All Rights Reserved Tumor-associated macrophages: Are immunosuppressive and correlate with poor prognosis Depend on CSF-1R for survival Are blocked by cabiralizumab (FPA008) Cabiralizumab (FPA008): Targets Immuno-Suppressive Tumor-Associated Macrophages (

  58. Slide 58: Anti-Mouse CSF1R Creates Pro-inflammatory Environment

    Similar effects seen in CT26 xenograft and orthotopic pancreatic cancer models © 2016 Five Prime Therapeutics, Inc. All Rights Reserved Antibody to Mouse CSF1R Creates a Pro-inflammatory Environment with Elevated PD-L1 Expression in Multiple Models IgG IgG cmFPA008 cmFPA008 Relative Expression (norm

  59. Slide 59: Rationale for Combination Therapy: TAMs and Checkpoints

    © 2016 Five Prime Therapeutics, Inc. All Rights Reserved Rationale for Combination Therapy: TAMs and Checkpoints Inhibit T Cell-Mediated Killing Through Different Mechanisms CD8 T Cell Tumor Cell PD-1 PD-L1 TAM CSF-1R PD-L1/PD-1 suppresses T cells TAMs produce factors that inhibit T cells

  60. Slide 60: Cabiralizumab Program Partnered with BMS

    BMS: Combinations of cabiralizumab (FPA008) with Opdivo® and potentially other BMS products Five Prime: Leads current trials in I-O (Phase 1a/1b) & PVNS (Phase 2) Can combine cabiralizumab (FPA008) with future Five Prime assets © 2016 Five Prime Therapeutics, Inc. All Rights Reserved Cabiralizumab (

  61. Slide 61: Cabiralizumab Safety Summary from 54 Healthy Volunteers and RA Patients

    © 2016 Five Prime Therapeutics, Inc. All Rights Reserved Ascending doses up to 10 mg/kg delivered No MTD, DLTs, or related SAEs No Grade 3 or greater AEs Key Findings Grade 1 and 2 periorbital edema at 10 mg/kg single dose in 83% of normal human volunteers Reversible elevation in serum enzymes witho

  62. Slide 62: Cabiralizumab/Opdivo Combination Trial Remains on Track

    Cabiralizumab (FPA008)/Opdivo® Combination Trial in Multiple Tumor Settings Remains on Track Cabiralizumab + Opdivo® Cabiralizumab Monotherapy PANCREATIC 2nd-line RENAL 3rd-line OVARIAN 3nd-line GLIOBLASTOMA 2nd-line HEAD & NECK 2nd-line LUNG (NSCLC) Anti-PD-1 Naïve; 2nd-line PHASE 1b Cabiralizumab

  63. Slide 63: Maximal Reduction of Target Monocytes at Phase 1b Dose

    Maximal Reduction of Target Monocytes is Achieved in Peripheral Blood with Cabira at the Phase 1b Selected Dose Cabiralizumab (FPA008) also caused a dose-dependent reduction of serum markers of bone turnover in a previous study (CTX and TRAP5b) Patient 1 Patient 2 Patient 3 Patient 4 Patient 7 Patie

  64. Slide 64: Cabiralizumab in Pigmented Villonodular Synovitis (PVNS)

    © 2016 Five Prime Therapeutics, Inc. All Rights Reserved PVNS is: A CSF-1-driven orphan joint disease that is a rare, locally aggressive tumor of synovium Not lethal, but painful and with high morbidity No approved therapies Cabiralizumab (FPA008) has orphan drug designation in PVNS ~25,000 diffuse

  65. Slide 65: Cabiralizumab Phase 2 Trial in PVNS

    Cabiralizumab (FPA008) – Initiated Phase 2 Trial in PVNS Objective response May 2016 Initiated Phase 2 Phase 2: ~ 30 patients Phase 1: Dose Escalation Select dose for Phase 2 Study Objectives Range of motion Pain © 2016 Five Prime Therapeutics, Inc. All Rights Reserved

  66. Slide 66: Anticipated Clinical Progress and Disclosures 2017

    Anticipated Clinical Progress and Disclosures 2017 © 2016 Five Prime Therapeutics, Inc. All Rights Reserved Cabiralizumab (FPA008) Work with BMS to disclose data on I-O and PVNS programs in 2017 Seek guidance from regulatory agencies on a pivotal trial for PVNS Anticipate completing enrollment in cu

  67. Slide 67: FPA144 – Antibody Against FGFR2b-Overexpressing Tumors

    Helen Collins, M.D. Vice President, Clinical Development FPA144 – Antibody Against Fibroblast Growth Factor 2b (FGFR2b)-Overexpressing Tumors

  68. Slide 68: Our I-O Research Pipeline Is Diversified and Robust

    Our I-O Research Pipeline Is Diversified and Robust © 2016 Five Prime Therapeutics, Inc. All Rights Reserved CD8 T cell TAM Dendritic cell TReg NK cell Extracellular Proteins Tumor Cell Immune Cell Immune Cell

  69. Slide 69: FPA144 Effectively Recruits Tumor-Killing NK Cells

    FPA144 Effectively Recruits Tumor-Killing NK Cells Enhanced ADCC to increase NK cell recruitment FPA144: antibody specific to FGFR2b splice variant Natural Killer Cell Tumor Cell FGFR2b FPA144 FGF7, 10, 22 © 2016 Five Prime Therapeutics, Inc. All Rights Reserved

  70. Slide 70: FPA144 Re-programs the Tumor Microenvironment

    FPA144 Re-programs the Tumor Microenvironment in a Syngeneic Mouse Model; Results in NK and T Cell Recruitment Ab Control Treated Tumor FPA144 Treated Tumor NK cells T cells PD-L1 © 2016 Five Prime Therapeutics, Inc. All Rights Reserved Powers et al, AACR 2016

  71. Slide 71: Gastric Cancer Patients with Amplified FGFR2 Have Reduced Survival

    Gastric Cancer Patients Whose Tumors Have Amplified FGFR2 Gene Have Reduced Survival* *Seo, Oncotarget 2016

  72. Slide 72: FPA144: Focused Development in Selected Patients

    Proprietary IHC assay identifies patients Gastric cancer Gene for FGFR2b is highly amplified in ~5% Worldwide patient prevalence ~80,000 Lower levels of FGFR2b expression may represent additional subgroups Bladder cancer IHC analysis of 387 archival primary UC samples showed that FGFR2b is overexpre

  73. Slide 73: FPA144 Phase 1 Study Is Currently Enrolling FGFR2b+ Patients

    Active PART 1 Dose Escalation PART 2 Selected Patients (up to 30/arm) Study Objectives PART 1A: Dose Escalation* in Solid Tumors PART 1B: Gastric Cancer IHC Moderate Gastric IHC Negative Gastric IHC Positive Bladder IHC High Gastric All at 15 mg/kg q2w Safety PK Objective response rate and duration

  74. Slide 74: Initial Monotherapy Antitumor Activity of FPA144 in Gastric Patients

    © 2016 Five Prime Therapeutics, Inc. All Rights Reserved Initial Monotherapy Antitumor Activity of FPA144 in FGFR2b+ Gastric Patients in Multiple Dosing Cohorts* *ASCO 2016 Data cutoff was April 1, 2016

  75. Slide 75: FPA144 Demonstrated Initial Monotherapy Activity and Tolerability

    © 2016 Five Prime Therapeutics, Inc. All Rights Reserved FPA144 Demonstrated Initial Monotherapy Activity and Tolerability* Outcome FPA144 Treated (N=9) ORR ** (95% CI) 33% (7%, 70%) Best Objective Response (%) Complete Response 0 (0%) Partial Response 3* (33%) Stable Disease 4 (44%) Progressive Dis

  76. Slide 76: Anticipated Clinical Progress and Disclosures 2017

    Anticipated Clinical Progress and Disclosures 2017 © 2016 Five Prime Therapeutics, Inc. All Rights Reserved FPA144 Plan to submit abstract for ASCO 2017 Seek guidance from regulatory agencies on a pivotal trial in gastric cancer Planned combination trials to allow advancement of FPA144 into earlier

  77. Slide 77: Thank You

    Thank You Rusty Williams, M.D., Ph.D. Founder, President & Chief Executive Officer

Five Prime Therapeutics — Investor Day (December 2016) on 6ix